(Lésions de la cavité buccale associées au tabac : Partie II. Lésions malignes)
Sayed M. Mirbod, DDS, M.Sc.
La première partie de la série des deux articles traitait des lésions bénignes de la cavité buccale associées au tabac. Dans cette dernière partie, nous décrivons les lésions malignes qui y sont associées, ainsi que les principes fondamentaux de la biopsie et les stratégies dintervention que les professionnels dentaires peuvent utiliser pour prévenir les lésions précancéreuses ou malignes primaires.
Mots clés MeSH : mouth neoplasms; smoking/adverse effects; tobacco, smokeless/adverse effects
© J Can Dent Assoc 2000; 66:308-11
Oral cancer accounts for about 3-4% of all cancers. Of all oral cancers, 96% are carcinomas and 4% are sarcomas. The most common type of oral cancer is squamous-cell carcinoma, constituting about 90% of oral malignancies.1
Tobacco smoke contains a number of hydrocarbons that are powerful carcinogens. Tobacco smoke and unburned tobacco, used in chewing or snuff dipping, also contain several potent nitrosamines. These chemicals are all DNA-toxic carcinogens that may play a key role in the initiation and promotion of specific types of cancer such as squamous-cell carcinoma and verrucous carcinoma2 (Figs. 1 and 2).
Although the most common intraoral site for carcinoma is the posterior ventrolateral border of the tongue, the floor of the mouth is also frequently affected. Together with the retromolar region, these areas form a horseshoe-shaped zone of increased cancer susceptibility and the location of about 75-85% of all intraoral cancers3 (Fig. 3).
Squamous-cell carcinoma of the tongue is the most common oral malignancy, accounting for 25-40% of all oral carcinomas. Characteristically, it appears as an indurated, nonhealing ulcer with elevated margins. Occasionally, the neoplasm may have a prominent exophytic as well as an endophytic growth pattern. Metastasis from the tongue to ipsilateral lymph nodes of the neck is relatively common.
The floor of the mouth is the second most common intraoral location for squamous-cell carcinomas, accounting for 15-20% of all cases. The usual appearance is a red or white, painless, nonhealing, indurated ulcer. Occasionally, the lesion may widely infiltrate the soft tissues of the floor of the mouth, causing decreased mobility of the tongue, characterized clinically by alteration of speech. Altered speech, persistent hoarseness or chronic cough with or without bloody sputum (hemoptysis) may indicate laryngeal metastasis or malignancy.
Lip carcinomas account for 25-30% of all oral cancers. The slower growing, more common carcinoma of the lower lip has a better prognosis than upper-lip lesions. Lesions occur on the vermilion border and may appear as chronic nonhealing ulcers or exophytic lesions that are occasionally verrucous. Deeper invasion, clinically characterized by induration, occurs later in the course of the disease, and metastases to submental and submandibular lymph nodes are more likely with histologically less-differentiated lesions and more advanced lesions.
Any chronic nonhealing ulcer present for two or more weeks must be biopsied to rule out squamous-cell carcinoma. Fine-needle aspiration for suspected cervical nodes, plain radiographs of the jaw bones if bone involvement is suspected, bone scans and computed tomography can also be helpful in diagnosis.1 In most cases, treatment of oral cancers is best achieved by surgery or radiation, or a combination of these two methods.4 Current research into chemotherapy and photodynamic therapy may provide additional modalities in the future.
Verrucous carcinoma, a less common tumour, represents 4.5-9% of oral squamous-cell carcinomas. It typically presents as a slowly enlarging, gray or white, warty, exophytic growth on the buccal mucosa or gingiva of older men with an average age of 65 years at time of diagnosis.5 The most common sites of occurrence within the oral cavity are the buccal mucosa, gingiva and the alveolar ridge; other sites of involvement include the palate, floor of the mouth and lip. Microscopically, verrucous carcinoma appears as a papillary or verrucous low-grade (i.e., well-differentiated) squamous-cell carcinoma. There is overlying hyperortho- or parakeratosis, or both, and prominent well-polarized bulbous rete pegs that have a pushing, rather than infiltrating quality at the base of the tumour. An intense mixed inflammatory infiltrate may surround and blend with the tumour and may contribute to the occasional misdiagnosis of verrucous carcinoma as pseudoepitheliomatous hyperplasia or chronic hyperplastic candidiasis. When a diagnosis of verrucous carcinoma is considered, a full-thickness biopsy down to the periosteum or submucosa must be performed to minimize the chances of misdiagnosis.6 Because of its superficial, cohesive growth pattern and sharply demarcated margins, verrucous carcinoma is ideally suited for treatment by surgical excision or laser therapy.
As dentists are in a position to notice malignant transformations in the oral cavity of habitual tobacco users, it is important for them to be familiar with the clinical characteristics of common oral carcinomas, which are summarized in Table 1. Table 2 provides a list of warning signs and symptoms for oral carcinomas that can be used by the general practitioner to determine the need for biopsy and referral to a specialist.
Basic Principles of BiopsyThe standard procedure in the diagnosis of precancerous and cancerous lesions of the mouth is a biopsy. Certain principles are important to the successful procurement and submission of tissues for histologic examination:
the site of the biopsy should be representative of the pathological process;
the tissue must be removed as atraumatically as possible;
an appropriate preservative should be used;
relevant clinical information should be provided to the oral pathologist.
In general, sufficient tissue should be removed from areas that show a clinical abnormality. The surgeon should avoid undue distortion of the specimen by squeezing, traction sutures or direct injections of local anesthetic and submit the specimen to an oral pathology laboratory in 10% neutral buffered formalin. Reconstitution of formalin that has dried out must be avoided; specimens should not be sent in saline and, in extremely cold weather, the specimen container should not be mailed. The requisition sheet should include the patients name, age, sex, location of the lesion, its morphologic description, its biological behaviour including signs and symptoms, any radiographic findings, any pertinent medical history and any previous pathologic diagnoses of the mouth.
Prevention and Intervention
Dental professionals may adopt preventive strategies to reduce their patients chances of developing precancerous lesions or primary malignancies, and to slow progression of established precancerous lesions. Excessive use of tobacco and alcohol are the major contributing factors in the etiology of oral squamous-cell carcinoma and, therefore, the major focus for prevention programs. In general, there has been a reluctance to use medication to treat these addictions because they are not viewed as medical disorders but as lifestyle choices; thus, psychological approaches have been emphasized. Combined psychological and pharmacological approaches are often synergistic. Physician advice to stop smoking increases cessation rates compared with the absence of such advice.7 Furthermore, recent studies have shown that motivated dentists with staff support and access to information on tobacco cessation counselling are able to contribute to tobacco control measures at rates comparable to those reported in medical settings.8,9
Although treatment options for tobacco addiction are rapidly expanding, practice guidelines established in 1996 by the American Agency for Health Care Policy and Research still provide valuable information regarding actions and strategies that must be taken by the clinician to encourage tobacco cessation.7 These guidelines should be carefully reviewed by anyone attempting to incorporate a tobacco cessation protocol into his or her dental practice.
Pharmacological approaches to tobacco addiction involve the use of nicotine chewing gum, nicotine patches or bupropion hydrochloride (Zyban). All currently available therapies appear to be equally efficacious, approximately doubling the quit rate achieved with placebo.10 (Note: Hughes and others10 provide appropriate dosage protocols.) Pharmacological approaches to alcohol addiction are relatively new, and the most efficacious appear to be acamprosate and naltrexone; although other drugs have been used, supporting evidence is suboptimal.11
Once clinically visible lesions such as leukoplakia or erythroplakia have developed, pharmacotherapeutic agents may be used. This strategy attempts to prevent further progression of potentially precancerous lesions and is, therefore, termed chemoprevention. The major chemopreventive agents are retinoids (vitamin A analogues), but nonretinoid agents (e.g., interferon and green tea) are being studied.12
It seems that only a small proportion of lesions actually regress permanently and these tend to be small and homogeneous. Most lesions appear to return once the chemopreventive agents are discontinued.13 Nevertheless, chemopreventive agents are undergoing clinical trials and may be useful in selected cases.14 A major challenge in chemoprevention is to find the histologically detectable biochemical marker molecules that would best reflect neoplastic transformation or progression in terms of deranged-cell proliferation and oncogenes. This is necessary to determine whether the therapeutic intervention is effective at a molecular level by carrying out serial biopsies. Although clinical lesions may disappear, cellular changes may still be detectable microscopically and are reason for recurrence.
A more detailed description of preventive oncology is beyond the scope of this paper, but we highly recommend that tobacco and alcohol histories be a part of all initial and follow-up appointment protocols and that dentists become familiar with referral mechanisms to local or national foundations that treat addictions. Information on addiction foundations in Canada can be obtained from the Canadian Centre on Substance Abuse in Ottawa ((613) 235-4048) or from any provincial ministry of health. Currently, addiction counsellors are not governed by a single regulatory body and, in most if not all provinces, there are no licensure requirements. Many provincial addiction foundations offer library resources as well as courses focused on specific addictions for any member of the public, including health professionals.
Remerciements : Les auteurs tiennent à exprimer leur profonde reconnaissance aux Drs Shirley Gelskey et David Singer pour leur aide dans la révision du manuscrit.
Le Dr Mirbod est résident de deuxième année en parodontie, à lUniversité du Manitoba.
Le Dr Ahing est spécialiste en pathologie buccale et chef de la section de diagnostic buccal, à lUniversité du Manitoba.
Écrire au : Dr Sayed M. Mirbod, Clinique de parodontie, Faculté de médecine dentaire, Université du Manitoba, 790, av. Bannatyne, Winnipeg, MB R3E 0W2. Courriel : firstname.lastname@example.org.
Les auteurs nont aucun intérêt financier déclaré.
1. Silverman S Jr. Oral cancer. 4th ed. Hamilton: B.C. Decker; 1998. p. 25-33.
2. Chambers MS, Jacob RF. How carcinogens cause cancer. Tex Dent J 1994; 111:13-9.
3. McGaw WT, Pan JT. Cancer of the gingiva, buccal mucosa, and palate. J Can Dent Assoc 1996; 62:146-50.
4. Barasch A, Safford M, Eisenberg E. Oral cancer and oral effects of anticancer therapy. Mt Sinai J Med 1998; 65:370-7.
5. Spiro RH. Verrucous carcinoma, then and now. Am J Surg 1998; 176:393-7.
6. Florin EH, Kolbusz RV, Goldberg LH. Verrucous carcinoma of the oral cavity. Int J Dermatol 1994; 33:618-22.
7. Fiore MC, Baker DL. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA 1996; 275:1270-80.
8. Smith SE, Warnakulasuriya KA, Feyerabend C, Belcher M, Cooper DJ, Johnson NW. A smoking cessation programme conducted through dental practices in the UK. Br Dent J 1998; 185:299-303.
9. Severson HH, Andrews JA, Lichtenstein E, Gordon JS, Barckley MF. Using the hygiene visit to deliver a tobacco cessation program: results of a randomized clinical trial. JADA 1998; 129:993-1006.
10. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281:72-6.
11. Swift RM. Drug therapy for alcohol dependence. New Engl J Med 1999; 340:1482-90.
12. Lingen MW. Understanding the biology of oral cancer and chemoprevention. CDS Rev 1998; 91:24-8.
13. Evans TRJ, Kaye SB. Retinoids: present role and future potential. Br J Cancer 1999; 80:1-8.
14. de Vries N, van Zandwijk N, Pastorino U. Chemoprevention of head and neck and lung (pre)cancer. Recent Results Cancer Res 1999; 151:13-25.
Le Centre de documentation de lADC
Le Centre de documentation de lADC peut davantage renseigner les membres sur les effets bucco-dentaires du tabac de même que les aider à effectuer des recherches sur Medline à ce sujet. Communiquez avec le Centre de documentation pour obtenir une liste des frais et des services au 1-800-267-6354, poste 2223 ou au (613) 523-1770, poste 2223, par télécopieur au (613) 523-6574 ou par courriel à email@example.com.